The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

January 25th 2021, 10:30pm


Breast cancer oncologists explore more recent advances using oral chemotherapies to treat metastatic breast cancer.

FDA Approves First Oral Therapy for Lupus Nephritis

January 25th 2021, 10:12pm


Voclosporin, the first FDA-approved oral therapy for lupus nephritis, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.

First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC

January 23rd 2021, 3:30pm


Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.

Review Examines Use of Biologics in Atopic, Inflammatory Diseases

January 16th 2021, 12:30pm


A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.

Innovative Procedure Minimizes Potential Prostate Cancer Radiation Side Effects

January 15th 2021, 9:30pm


Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.

Study Compares Mepolizumab, Benralizumab for Eosinophilic Asthma

January 15th 2021, 5:03pm


Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.

SMIs Linked to Reduced Exacerbations, Readmissions in COPD

January 15th 2021, 12:00pm


Investigators using real-world data found that patients receiving treatment from slow mist inhalers (SMIs) had fewer exacerbations and hospitals readmissions compared with patients using dry powder inhalers (DPIs).

Ensuring a Path of Success for Drug Repurposing in PAH

January 14th 2021, 9:15pm


Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.

Natural Killer Cells Could Play Key Role in Fight Against MM

January 12th 2021, 6:16pm


Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).

What Are the Real-Life Effects of Erenumab Discontinuation?

January 11th 2021, 4:37pm


Data on patients with migraine who stopped erenumab treatment show that over half of patients had an early disease worsening while the remaining patients maintained their responder status during weeks 1 through 4 post treatment.